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Abstract
The effect of cGMP (cyclic GMP) dependent protein kinase 1-β (PKG1-β) and cGMP analogues on
transcriptional activity and replication of human immunodeficiency virus type 1 (HIV-1) was
investigated. Transfection of PKG1β expression plasmid increased expression from an HIV-1 LTR-
reporter as well as from an infectious HIV-1 molecular clone, pNL4-3. Treatment of HIV-1 AD8-
infected monocyte derived macrophages (MDMs) with cGMP agonists and cGMP antagonists
caused respectively increased and decreased virus replication. These findings provide evidence that
cGMP and PKG serve to regulate HIV-1 infection in human cells.
Findings
Previously nitric oxide (NO) was postulated to have a neg-
ative effect on HIV-1 replication through a cGMP-inde-
pendent route [1]. However, it was not characterized as to
how this cGMP-independent effect manifested mechanis-
tically. On the other hand, it is well-accepted that a major
intracellular signaling pathway for NO is through a
cytosolic-guanylate cyclase linked cGMP-dependent pro-
tein kinase, PKG, pathway [2]. cGMP/PKG has been
shown to activate abundantly both CREB [3] and NF-κB
[4,5]. Interestingly, to our knowledge, no systematic
investigation of cGMP/PKG's activity on the HIV-1 LTR
has been reported to date.
To address how cGMP/PKG might influence HIV-1 LTR-
directed expression, we transfected HeLa cells with a LTR-
luciferase reporter with or without a Tat-plasmid [6-9]-
and assayed for expression with or without simultane-
ously co-transfecting a PKG1β-expression vector [10]-
(Figure 1). We found that PKG1β-alone activated reporter
expression by approximately 4 fold (also see Figure 2B)
while Tat-alone activated expression by >45 fold (Figure
1A). Co-transfection of LTR-luciferase + Tat + PKG1β acti-
vated expression cumulatively to >175 fold (Figure 1A).
These results are consistent with PKG1β inducing LTR-
driven expression whether in the absence or presence of
Tat.
To verify more physiologically the above LTR-reporter
assay, we next checked the effect of PKG1β on an HIV-1
infectious molecular clone, pNL 4-3 (Figure 1B). Here,
increasing amounts of PKG1β-plasmid were transfected
into cells with a constant level of pNL 4-3. Viral proteins
expressed from the HIV-1 molecular clone were then
measured. Using HIV-specific hyper-immune sera in
Western blots, we observed that PKG1β increased pNL 4-
3 expression in a dose dependent manner (Figure 1B,
lanes 2 – 6). To investigate whether the intact function of
PKG1β was needed for this activity, we created two loss-
of-function PKG1β deletion mutants (Figure 2A). Both
deletion mutants were unable to activate either a LTR-
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PKG1β activates expression from the HIV-1 LTR Figure 1
PKG1β activates expression from the HIV-1 LTR. A) Activation of HIV-1 LTR luciferase by PKG1β. HeLa cells were cultured in 
medium with 0.1% fetal bovine serum and transfected as indicated with HIV-1 LTR luciferase reporter plasmid in the absence 
and presence of Tat, and with a PKG1-β expression plasmids. PKG1β was found to increase Tat dependent transcriptional 
activity of the HIV-1 LTR by four fold. B) Co-transfection of PKG1β and HIV-1 infectious molecular clone, pNL4-3, resulted in 
dose dependent increase in viral protein expression. Expression of FLAG-tagged transfected PKG1β (top panel) and HIV-1 viral 
proteins are shown by Western blotting.Retrovirology 2007, 4:91 http://www.retrovirology.com/content/4/1/91
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reporter (Figure 2B) or an HIV-1 infectious molecular
clone (Figure 2C).
Optimal PKG activity is dependent on activation by cGMP
[11]. While over expression of exogenously transfected
PKG offered significantly measureable effects (Figures 1,
2), we wished to understand next how cell endogenous
PKG might act mechanistically in response to cGMP treat-
ment. Elsewhere, it was reported that NF-κB p65, p52, and
p50 are substrate proteins activated by PKG-mediated
phosphorylation. Because expression of the HIV-1 LTR is
regulated by NF-κB [12,13], we asked if cGMP activated
NF-κB in our experimental.
To assess if NF-κB was activated by cGMP, we assayed for
enhanced nuclear localization of NF-κB protein p65,
which is one measure of activation [14,15]. We treated
cells with a cGMP agonist, 8-pCPT-cGMP, and compared
results to cells treated with a known NF-κB activator,
tumor necrosis factor alpha, TNFα. When cytosolic and
nuclear p65 proteins were assayed, we observed that 8-
pCPT-cGMP behaved quantitatively very similarly to
TNFα in inducing increased NF-κB p65-translocation into
the nucleus (Figure 3A). This result supports that PKG-
activation of HIV-1 (Figures 1, 2) acts through an NF-κB-
mediated process. To confirm that PKG1β can directly
activate NF-κβ activity, we transfected a NF-κβ luciferase
reporter into cells with or without a co-transfected PKG1β
Intact PKG1 β is required for activation of gene expression Figure 2
Intact PKG1 β is required for activation of gene expression. A) Schematic representations are shown of full length PKG1β 
(pCMV-PKG1β FLAG) and two deletion mutants, pCMV-PKG1β 1–417 FLAG and pCMV-PKG1β ∆349FLAG. Transfected cell 
lysates (right panel) were analyzed by Western blotting using anti-FLAG antibody for expression. B) Full length PKG1β, but not 
its deletion mutants, activated LTR-luciferase expression. HeLa cells were transfected with the indicated plasmids. C) Full 
PKG1β, but not its deletion mutants, activated pNL4-3-expression. Plasmids were transfected into HeLa cells as indicated. C- 
and N-terminus deletions of PKG1β resulted in loss of activity.Retrovirology 2007, 4:91 http://www.retrovirology.com/content/4/1/91
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Treatment of HeLa cells with cGMP agonist, 8-(4-chlorophenylthio)guanosine 3'.5'-cyclic monophosphate (8-pCPT-cGMP),  increased NF-κβ p65 in the nucleus Figure 3
Treatment of HeLa cells with cGMP agonist, 8-(4-chlorophenylthio)guanosine 3'.5'-cyclic monophosphate (8-pCPT-cGMP), 
increased NF-κβ p65 in the nucleus. A) HeLa cells were mock treated or treated with TNFa or 8-pCPT-cGMP as indicated. 
Nuclear and cytoplasmic fractions were collected and assayed for NF-κβ p65 by Western blotting. Both TNFα and 8-pCPT-
cGMP were found to increase nuclear NF-κβ p65 while commensurately decreasing cytoplasmic NF-κβ p65. Western blotting 
for tubulin controlled for subcellular fractionations. Quantifications of relative distributions of NF-κβ p65 are shown at bot-
tom. B) PKG1β increases expression of NF-κB dependent luciferase. HeLa cells were transfected with NF-κB luciferase 
reporter plasmid in the presence or absence of co-transfected PKG1β expression plasmid. Cells were harvested 24 hours 
post-transfection, and cell lysates were assayed for luciferase activity as indicated.Retrovirology 2007, 4:91 http://www.retrovirology.com/content/4/1/91
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expression plasmid (Figure 3B). Results from this assay
showed that NF-κβ-dependent luciferase activity was
indeed elevated by PKG1β.
A more direct verification of cGMP/PKG's role in HIV-1
replication can be established using chemical agonists
and antagonists of this pathway seeking for effects on viral
infection. Because the NO/cGMP signaling pathway has
been reported to function potently in cells of macrophage
lineage, we performed infection of monocyte derived
macrophages (MDMs) using HIV-1 strain AD8 [16,17].
MDMs infected with AD8 were treated individually with
three different drugs. We employed two cGMP agonists
(8-pCPT-cGMP, and Sp-8-pCPT-cGMP) and one cGMP
antagonist (Rp-8-pCPT-cGMPs) and monitored their
impact on HIV-1 replication. Informatively, in two sepa-
rate experiments, both agonist drugs increased virus repli-
cation over control-treated infection, while the cGMP-
antagonist drug decreased (or did not affect) virus replica-
tion (Figure 4).
Here, we report evidence that both in the absence and
presence of Tat the cGMP/PKG pathway can serve to mod-
ulate HIV-1 expression/replication. Understanding how
HIV-1 LTR expression is affected by ambient cellular path-
ways [18-20] may help to address potential approaches
for treating latent HIV-1 infection [21]. The current find-
ings may be important because cGMP is a ubiquitous sec-
ond messenger that affects multiple cellular pathways in
most, if not all, cells. Accordingly, cGMP-influenced path-
ways are likely to interdigitate with some of the signaling
routes utilized by HIV-1 in infected cells [22]. Addition-
ally, because many cGMP chemical agonists and antago-
nists are available [23,24], practical chemotherapeutic
interventions in these pathways (if they should be useful
for anti-viral purposes) could be amenable.
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